Advertisement
YOU ARE HERE: LAT HomeCollectionsHyseq Inc
IN THE NEWS

Hyseq Inc

FEATURED ARTICLES
BUSINESS
November 12, 2002 | From Bloomberg News
Hyseq Inc. of Sunnyvale agreed to buy Variagenics Inc. for about $55.9 million in stock to accelerate development of a drug to dissolve blood clots and develop other products. Hyseq would exchange about 1.65 shares for each Variagenics share, the companies said. That values Variagenics, based in Cambridge, Mass., at $2.22 a share, more than double Friday's closing price of 96 cents. Shares of Hyseq fell 27 cents to $1.08 on Nasdaq.
ARTICLES BY DATE
BUSINESS
November 12, 2002 | From Bloomberg News
Hyseq Inc. of Sunnyvale agreed to buy Variagenics Inc. for about $55.9 million in stock to accelerate development of a drug to dissolve blood clots and develop other products. Hyseq would exchange about 1.65 shares for each Variagenics share, the companies said. That values Variagenics, based in Cambridge, Mass., at $2.22 a share, more than double Friday's closing price of 96 cents. Shares of Hyseq fell 27 cents to $1.08 on Nasdaq.
Advertisement
BUSINESS
May 14, 1996 | BARBARA MURPHY
BioSource International has asked Robert D. Weist to join its board of directors. Weist, the principal of a management consulting firm, will fill an existing vacancy, and the board is expected to accept him for a permanent term at the company's annual meeting in July. Weist has nearly three decades of experience in management and legal counsel positions in the pharmaceutical and biotechnology industries.
Los Angeles Times Articles
|